Oncotelic Therapeutics Inc Stock Price, News & Analysis

Sapu Nano (OTLC) announced that Sapu-003, the company's first intravenous Deciparticle™ formulation of everolimus, has entered a Phase 1 study in Australia and was presented at the 8th Australian Translational Breast Cancer Research Symposium on October 8, 2025. The trial (ACTRN12625001083482) is open for enrollment at leading Australian oncology centres for adults with advanced HR+/HER2– breast cancer and other mTOR-sensitive tumors who have exhausted standard therapies. The program is partnered with SOCRU, Ingenū, and Medicilon to support clinical execution, regulatory alignment, and product supply.

Sapu Nano, part of a joint venture involving Oncotelic Therapeutics (OTCQB: OTLC), has received approval from Australia's HREC to begin Phase 1 human clinical trials for Sapu003, an injectable form of Everolimus for breast cancer treatment.

The key innovation lies in Sapu003's delivery method: While the FDA-approved oral version (Afinitor®) has only 10% bioavailability, Sapu003 uses proprietary Deciparticle™ technology for intravenous delivery, enabling 100% drug absorption. This breakthrough could potentially improve efficacy in treating breast cancer, kidney cancer, and certain rare tumors.

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself as a key player in the biotechnology sector, focusing on developing treatments for cancer and rare diseases. Under the leadership of CEO Dr. Vuong Trieu, the company is leveraging artificial intelligence and nanomedicine to innovate in biotechnology.

The company's intellectual property portfolio includes approximately 500 patent applications and 75 granted patents. Oncotelic is specifically targeting difficult-to-treat cancers such as glioblastoma and pancreatic cancer, along with rare pediatric disorders, addressing significant unmet medical needs in these areas.

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself as a key player in the biotech industry, focusing on developing treatments for aggressive cancers and pediatric rare diseases. Under CEO Dr. Vuong Trieu's leadership, the company is leveraging artificial intelligence, nanomedicine, and novel clinical models to advance its therapeutic pipeline.

The company's intellectual property portfolio includes over 500 patent applications and 75 issued patents. Oncotelic is specifically targeting difficult-to-treat conditions such as glioblastoma and pancreatic cancer, aiming to address significant unmet medical needs in these areas through RNA-based and immunotherapy approaches.

Oncotelic Therapeutics (OTCQB: OTLC) has provided a comprehensive update on its clinical and regulatory progress over the past two years. The company's pipeline features multiple late-stage drug candidates targeting oncology and rare diseases.

Key programs include OT-101 in Phase 3 for pancreatic cancer, OXi4503 advancing to Phase 3 for AML/MDS, CA4P/Fosbretabulin for oncology, AL-101 in Phase 2 for Parkinson's and sexual dysfunctions, and AL-102 for Alzheimer's disease. The company is also developing pediatric rare disease programs and a nanomedicine pipeline utilizing the 505(b)(2) pathway for expedited approval.

Oncotelic Therapeutics (OTCQB: OTLC) highlighted the contributions of Chairman and CEO Dr. Vuong Trieu and provided an update on its clinical pipeline. Dr. Trieu, a renowned industry pioneer, has an extensive portfolio of over 500 filed patents and 75 issued patents covering various therapeutic areas.

His notable achievements include co-inventing Abraxane® (acquired for $2.9 billion) and developing Cynviloq™ (sold for $1.3 billion). The company's pipeline includes six key programs: OT-101 (Phase 3 for pancreatic cancer), OXi4503 (Phase 2 in AML/MDS), CA4P/Fosbretabulin, AL-101 (Phase 2 for Parkinson's), AL-102 (discovery stage), and pediatric rare disease programs.

Oncotelic Therapeutics (OTCQB: OTLC) showcased its robust pipeline and highlighted the intellectual property contributions of CEO Dr. Vuong Trieu. Dr. Trieu's portfolio includes over 500 filed patents and 75 issued patents, with notable achievements including co-inventing Abraxane® (acquired for $2.9 billion) and developing Cynviloq™ (sold for $1.3 billion).

The company's pipeline includes multiple clinical-stage assets: OT-101 (Phase 3 for pancreatic cancer), OXi4503 (Phase 2 in AML/MDS), CA4P/Fosbretabulin (late-stage oncology), AL-101 (Phase 2 for Parkinson's), AL-102 (discovery stage for Alzheimer's), and pediatric rare disease programs targeting orphan indications.

Oncotelic Therapeutics (OTCQB: OTLC) has highlighted a new peer-reviewed publication demonstrating the link between TGFB2 expression and survival rates in younger pancreatic cancer patients. The study revealed that high TGFB2 expression significantly reduced overall survival in patients under 65 years, with median survival of 17.9 months versus 66.9 months for those with low expression.

The research supports further evaluation of the company's investigational antisense drug OT-101 (trabedersen) as a TGFB2-targeted treatment for pancreatic ductal adenocarcinoma (PDAC). Clinical data from the OT-101 P001 PDAC study showed promising results, with a median overall survival of 12.7 months in a treated subset with low IL-6.

Oncotelic Therapeutics (OTCQB: OTLC) has published a groundbreaking study in the International Journal of Molecular Sciences identifying TGFB2 gene methylation as a positive prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). The research, conducted in collaboration with Sapu Biosciences, revealed that patients with high TGFB2 methylation and low immune markers showed a significant median overall survival exceeding 50 months.

The findings support the development of OT-101, Oncotelic's investigational antisense oligonucleotide targeting TGFB2 mRNA. The study utilized PDAOAI, the company's AI-powered chatbot platform, for literature mining and analysis, demonstrating the integration of artificial intelligence in scientific research.